MGNX Forecast. What You Should Know.
MGNX Historical Ratings and Targets
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The... MGNX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.